- Home
- AACT vs CVAC Comparison
AACT vs CVAC Comparison
Compare AACT & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- CVAC
- Stock Information
- Founded
- AACT 2021
- CVAC 2000
- Country
- AACT United States
- CVAC Germany
- Employees
- AACT N/A
- CVAC N/A
- Industry
- AACT
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- CVAC Health Care
- Exchange
- AACT Nasdaq
- CVAC Nasdaq
- Market Cap
- AACT 697.5M
- CVAC 764.4M
- IPO Year
- AACT 2023
- CVAC 2020
- Fundamental
- Price
- AACT $11.30
- CVAC $5.44
- Analyst Decision
- AACT
- CVAC Buy
- Analyst Count
- AACT 0
- CVAC 3
- Target Price
- AACT N/A
- CVAC $9.00
- AVG Volume (30 Days)
- AACT 643.7K
- CVAC 2.1M
- Earning Date
- AACT 01-01-0001
- CVAC 08-14-2025
- Dividend Yield
- AACT N/A
- CVAC N/A
- EPS Growth
- AACT N/A
- CVAC N/A
- EPS
- AACT 0.36
- CVAC 0.87
- Revenue
- AACT N/A
- CVAC $566,039,775.00
- Revenue This Year
- AACT N/A
- CVAC N/A
- Revenue Next Year
- AACT N/A
- CVAC $24.04
- P/E Ratio
- AACT $31.27
- CVAC $6.34
- Revenue Growth
- AACT N/A
- CVAC 787.60
- 52 Week Low
- AACT $10.65
- CVAC $2.37
- 52 Week High
- AACT $11.62
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- AACT 45.02
- CVAC 68.03
- Support Level
- AACT $11.27
- CVAC $4.07
- Resistance Level
- AACT $11.32
- CVAC $5.58
- Average True Range (ATR)
- AACT 0.06
- CVAC 0.20
- MACD
- AACT -0.02
- CVAC 0.07
- Stochastic Oscillator
- AACT 14.67
- CVAC 83.08
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.